Induction of Clinical Response Using Rifaximin in Crohn's Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by University of Washington.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Salix Pharmaceuticals
Information provided by (Responsible Party):
Scott Lee, University of Washington
ClinicalTrials.gov Identifier:
NCT00603616
First received: January 16, 2008
Last updated: June 13, 2012
Last verified: June 2012

January 16, 2008
June 13, 2012
November 2008
December 2012   (final data collection date for primary outcome measure)
Evaluate the efficacy of rifaximin 550 mg bid compared to placebo in achieving clinical response in moderate to severe Crohn's Disease (CD) subjects as determined by a > 100 point decrease in the Crohn's Disease Activity Index (CDAI) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Evaluate the efficacy of rifaximin 550 mg bid compared to placebo in achieving clinical response in moderate to severe CD subjects as determined by a >100 point decrease in the Crohn's Disease Activity Index (CDAI) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00603616 on ClinicalTrials.gov Archive Site
  • Evaluate the efficacy of rifaximin compared to placebo at inducing clinical remission in CD subjects [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Evaluate the safety profile of rifaximin in subjects with active CD [ Time Frame: 16 weeks for those subjects who do not cross over, 32 weeks for those who do cross over ] [ Designated as safety issue: Yes ]
  • Evaluate the effect rifaximin has on the quality of life in subjects with CD compared to placebo [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Evaluate if there are any clinical parameters which might predict response to rifaximin [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Compare mean changes in CDAI scores between rifaximin and placebo treated subjects [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Evaluate the efficacy of rifaximin compared to placebo at inducing clinical remission in CD subjects [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Evaluate the safety profile of rifaximin in subjects with active CD [ Time Frame: 16 weeks for those subjects who do not cross over, 32 weeks for those who do cross over ] [ Designated as safety issue: Yes ]
  • Evaluate the effect rifaximin has on the quality of life in subjects with CD compared to placebo [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Evaluate if there are any clinical parameters which might predict response to rifaximin [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Compare mean changes in CDAI scores between rifaximin and placebo treated subjects [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Use proteomics to discover novel biomarkers to predict response to rifaximin and form hypotheses on rifaximin mechanism of action [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Identify protein profile differences between CD and UC subjects using serum proteomic analysis [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Induction of Clinical Response Using Rifaximin in Crohn's Disease
A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease

Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces.

The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.

Inflammatory bowel disease (IBD) is a debilitating chronic inflammatory disease conventionally categorized into Crohn's disease (CD) and Ulcerative Colitis (UC). CD affects nearly 630,000 people in North America with up to 50,000 new people being diagnosed every year. It is a chronic debilitating disease characterized by abdominal pain, malnutrition, bloody diarrhea, fistula formation, intestinal perforations and strictures, and even extra-intestinal manifestations such as joint pains and skin rashes. Nearly 80% of people with CD will need surgical treatment at some point in their disease process. The majority of CD subjects are diagnosed in young adulthood thereby subjecting them to many decades of discomfort and medical intervention.

Antibiotics have been used to treat CD with variable response rates. The basis for antibiotic therapy is that breakdown of the integrity of the mucosal barrier in the gastrointestinal (GI) tract leads to a heightened inflammatory response to commensurate luminal bacteria. By changing the composition or bacterial load in the intestinal lumen, it may be possible to alter the immune response. Ciprofloxacin (Cipro) and metronidazole (Flagyl) are the best studied antibiotics that have shown efficacy, but the effect is temporal and long term use can lead to serious side effects. Rifaximin is a recent FDA approved antibiotic with broad spectrum of activity, excellent safety profile, and minimal absorption from the GI tract. Open label and small studies in IBD subjects show response rates up to 80% in CD subjects. These studies were limited however in that they were not randomized placebo controlled trials.

The investigators propose to conduct a randomized placebo controlled crossover trial of rifaximin in CD subjects to assess initial clinical response compared to placebo.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Crohn's Disease
  • Drug: Placebo Comparator
    Matching oral placebo pills to be taken twice daily for a total of 8 weeks
  • Drug: Rifaximin
    Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
    Other Name: Xifaxan
  • Placebo Comparator: 1
    Placebo pills
    Intervention: Drug: Placebo Comparator
  • Active Comparator: 2
    Rifaximin
    Intervention: Drug: Rifaximin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects, 18 to 80 years of age, inclusive, that can themselves provide written, informed consent and authorization of use of protected health information prior to any study-related procedures and who are, in the opinion of the investigator(s), likely to comply with all the requirements of the study
  • Subjects must have a prior diagnosis of CD established by endoscopy and clinical parameters as determined by the investigator(s) for at least 3 months prior to randomization
  • Subjects must be able to participate in all required follow-up visits and fill out all related documentation (e.g. symptom diary)
  • Subjects currently with moderately active disease defined as a CDAI 250-450
  • Concomitant medications:

    • If subjects are taking sulfasalazine or 5-ASA products prior to entry, the dose must be stable for at least 4 weeks prior to the randomization
    • If subjects are on azathioprine, 6-mercaptopurine, or methotrexate, they will have had to be on a stable dosage for at least 8 weeks
    • Subjects are allowed to be on corticosteroids at a dose equivalent to 20 mg or less of prednisone, IF the dose has been stable for a minimum of 2 weeks. Steroids must be held stable throughout the induction portion of the study. The maximum dose of budesonide must not exceed 9mg per day and must also have been stable for a minimum of 2 weeks.
    • No oral or intravenous antibiotics within 4 weeks prior to randomization
    • No current or past use of biological treatment within 6 weeks of randomization into study (e.g. infliximab)
    • If subjects have previously been on any of the above products but are no longer taking them, they should not have received any of the relevant therapeutic products within 4 weeks prior to randomization
    • No other experimental or non-FDA approved medications are allowed. If the subject has previously been on an experimental therapy, they must have not received the therapy within the prior 8 weeks prior to randomization
    • Subjects on concomitant medications for CD will not be allowed to change dosages during the study
  • If subjects are at increased risk of colorectal cancer (defined as having an 8-year history of pan-colitis or 12 year history of left sided colitis), they will need to have undergone a colonoscopy with pan-colonic surveillance biopsies within 2 years of the screening visit. The biopsies must be negative for dysplasia
  • Female or male subjects who are surgically sterilized or who are prepared to and agree to practice a double-barrier form of birth control from the screening visit through 30 days (females) and 30 days (males), respectively, from the last dose of study medication. Females who are more than 12 months post-menopausal are also eligible to participate in the study

Exclusion Criteria:

  • Evidence of active infection which may include any of the following

    • Febrile ( > 38.5ºC)
    • Positive blood culture within 2 weeks prior to randomization
    • Evidence of toxic megacolon or abscess
    • Positive stool culture for enteric pathogens, pathogenic ova or parasite, or a positive assay for C. difficile toxin at screening
  • Subjects with CDAI > 450
  • Any current use or use within the last 8 weeks of an investigational drug
  • Current or past use (within past 12 wks) of biological treatment
  • Current or use within the last 4 weeks of any oral or intravenous antibiotic
  • Anticipated increased dosage of any medication to treat CD
  • Anticipated need for surgery within 12 weeks
  • Known obstructive diseases of the gastrointestinal system
  • Medical conditions requiring in-patient hospitalization
  • Proctocolectomy, total colectomy, ileostomy, or stoma
  • Severe cardiopulmonary disease:

    • Congestive heart failure (NYHA Class III or IV)
    • Severe cardiovascular or peripheral vascular disease
    • Myocardial infarction, percutaneous coronary intervention, or bypass surgery within the past 6 months
  • Significant liver disease:

    • Levels of SGOT [AST], SGPT [ALT], or alkaline phosphatase > 2.5x the upper limit of the normal range for the laboratory performing test
    • History of cirrhosis
  • Renal insufficiency, defined as serum creatinine > 150% of the upper limit of the normal range for the laboratory performing the test
  • Abnormal hematology parameters defined as severe anemia with hemoglobin < 8.5 g/dL and/or white blood cell count of < 3,500/ul
  • Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)
  • History of dysplasia or carcinoma of the colon
  • Pregnant, lactating, or planning to become pregnant during the course of the investigational study
  • Known history of allergic reaction to rifaximin or allergy to any of the rifamycin antimicrobial agents (which include rifampin, rifabutin, and rifapentine)
Both
18 Years to 80 Years
No
Contact: Chelle Wheat, MPH 206-221-3338 chellew@medicine.washington.edu
Contact: Elisa Beebe, BS 206-543-3500 ebeebe@medicine.washington.edu
United States
 
NCT00603616
32871-B, 32871
No
Scott Lee, University of Washington
Scott Lee
Salix Pharmaceuticals
Principal Investigator: Scott D Lee, MD University of Washington
University of Washington
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP